Literature DB >> 9169820

An antiangiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma.

R Murata1, Y Nishimura, M Hiraoka.   

Abstract

PURPOSE: TNP-470, a synthetic analogue of fumagillin which is a natural product of Aspergillus fumigatus, has been noted as an angiogenesis inhibitor. Combined effects of TNP-470 with fractionated radiotherapy (RT) were investigated using a mouse tumor. METHODS AND MATERIALS: Tumors were early generations of mammary carcinoma in C3H/He mice. Treatments were initiated when tumors reached an average diameter of 4-5 mm. Tumor response was evaluated by tumor growth (TG) time assay and 50% tumor control dose (TCD50) assay. Tumors were irradiated locally under hypoxic conditions or in air. Five fractionated radiation doses were given in the TG time assay, whereas a single dose or 10 fractionated doses were given in the TCD50 assay. TNP-470 (100 mg/kg) was administered subcutaneously twice a week during and/or after RT.
RESULTS: In the TG time assay, significant delay of tumor growth was observed by TNP-470 alone (100 mg/kg x 2) compared with control tumors (p < 0.001), indicating that TNP-470 alone has an antitumor effect in vivo. When TNP-470 was administered during fractionated RT, no additional delay of tumor growth was observed. However, additive effects of TNP-470 was noted when it was given after the end of fractionated RT. In the TCD50 assay, no significant difference in TCD50s was observed between RT alone and RT combined with TNP-470 in single dose experiments. Hypoxic fraction of tumors calculated from the TCD50s was not affected significantly by administrating TNP-470 24 h before RT. On the other hand, in 10-fraction experiments, the TCD50 (RT with TNP-470, in air) was significantly higher than the TCD50 (RT alone, in air) (p < 0.005), indicating that TNP-470 given during fractionated RT decreased radiocurability. This negative effect of TNP-470 was not observed when TNP-470 was combined with fractionated RT given under hypoxic conditions.
CONCLUSION: The tumor control probability decreased by administrating TNP-470 during fractionated RT in air. This unexpected result may be attributable to partial inhibition of reoxygenation by TNP-470, because no significant difference was noted between the TCD50 (RT with TNP-470) and the TCD50 (RT alone) under hypoxic conditions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9169820     DOI: 10.1016/s0360-3016(96)00628-1

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  22 in total

1.  Augmentation of radiation response by motesanib, a multikinase inhibitor that targets vascular endothelial growth factor receptors.

Authors:  Tim J Kruser; Deric L Wheeler; Eric A Armstrong; Mari Iida; Kevin R Kozak; Albert J van der Kogel; Johan Bussink; Angela Coxon; Anthony Polverino; Paul M Harari
Journal:  Clin Cancer Res       Date:  2010-05-27       Impact factor: 12.531

Review 2.  To combine or not combine: the role of radiotherapy and targeted agents in the treatment for renal cell carcinoma.

Authors:  Christian Weiss; Björn Schulze; Annette Ottinger; Claus Rödel
Journal:  World J Urol       Date:  2013-05-08       Impact factor: 4.226

Review 3.  Combined vascular endothelial growth factor-targeted therapy and radiotherapy for rectal cancer: theory and clinical practice.

Authors:  Christopher G Willett; Sergey V Kozin; Dan G Duda; Emmanuelle di Tomaso; Kevin R Kozak; Yves Boucher; Rakesh K Jain
Journal:  Semin Oncol       Date:  2006-10       Impact factor: 4.929

4.  Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay.

Authors:  Morikazu Amano; Minoru Suzuki; Satoshi Andoh; Hajime Monzen; Kaoru Terai; Brent Williams; Chang W Song; Kevin H Mayo; Takeo Hasegawa; Ruud P M Dings; Robert J Griffin
Journal:  Int J Clin Oncol       Date:  2007-02-25       Impact factor: 3.402

Review 5.  Antiangiogenics: the potential role of integrating this novel treatment modality with chemoradiation for solid cancers.

Authors:  Dan G Duda; Rakesh K Jain; Christopher G Willett
Journal:  J Clin Oncol       Date:  2007-09-10       Impact factor: 44.544

6.  Design of antiangiogenic hypoxic cell radiosensitizers: 2-nitroimidazoles containing a 2-aminomethylene-4-cyclopentene-1,3-dione moiety.

Authors:  Yoshihiro Uto; Hideko Nagasawa; Cheng-Zhe Jin; Shinichi Nakayama; Ayako Tanaka; Saori Kiyoi; Hitomi Nakashima; Mariko Shimamura; Seiichi Inayama; Tomoya Fujiwara; Yoshio Takeuchi; Yoshimasa Uehara; Kenneth L Kirk; Eiji Nakata; Hitoshi Hori
Journal:  Bioorg Med Chem       Date:  2008-04-24       Impact factor: 3.641

7.  Increased tumor oxygenation and drug uptake during anti-angiogenic weekly low dose cyclophosphamide enhances the anti-tumor effect of weekly tirapazamine.

Authors:  J C Doloff; N Khan; J Ma; E Demidenko; H M Swartz; Y Jounaidi
Journal:  Curr Cancer Drug Targets       Date:  2009-09       Impact factor: 3.428

8.  Alterations in daily sequencing of axitinib and fractionated radiotherapy do not affect tumor growth inhibition or pathophysiological response.

Authors:  Bruce M Fenton; Scott F Paoni
Journal:  Radiat Res       Date:  2009-05       Impact factor: 2.841

9.  Metabolic tumor profiling with pH, oxygen, and glucose chemosensors on a quantum dot scaffold.

Authors:  Christopher M Lemon; Peter N Curtin; Rebecca C Somers; Andrew B Greytak; Ryan M Lanning; Rakesh K Jain; Moungi G Bawendi; Daniel G Nocera
Journal:  Inorg Chem       Date:  2013-10-21       Impact factor: 5.165

10.  Thrombospondin-1 inhibits nitric oxide signaling via CD36 by inhibiting myristic acid uptake.

Authors:  Jeff S Isenberg; Yifeng Jia; Julia Fukuyama; Christopher H Switzer; David A Wink; David D Roberts
Journal:  J Biol Chem       Date:  2007-04-05       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.